Clinical Trials

Biothera enters into immuno-oncology clinical trial collaboration with AstraZeneca

Biothera Pharmaceuticals has entred into a clinical collaboration with AstraZeneca to evaluate whether the combination of Biothera’s Imprime PGG and AstraZeneca’s durvalumab (IMFINZI) can decrease tumor volume in patients with primary untreated locally advanced head and neck cancer prior to surgical resection.

AstraZeneca’s lupus drug anifrolumab fails in Tulip 1 phase III trial

AstraZeneca’s lupus drug anifrolumab has failed to meet the primary endpoint in the Tulip 1 phase III trial.

Pfizer halts two trials of DMD drug domagrozumab

Pfizer said that it is terminating two ongoing trials - B5161002, a phase 2 safety and efficacy study and B5161004, an open-label extension study, which are assessing domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD).

Sonoma Pharmaceuticals’ HOCI demonstrates positive effect in acne study

Sonoma Pharmaceuticals has announced the results from a study, which assessed the use of its proprietary high-strength performance-stabilized HOCl (Hypochlorous Acid) in the management of acne vulgaris.

MXC gets approval for phase 2 trial of marijuana-based CogniCann in dementia

MGC Pharmaceuticals (MXC) has secured a key approval in Australia to launch a phase 2 trial to evaluate CogniCann, a medicinal cannabis compounded formulation, as a potential treatment of mild Dementia and Alzheimer’s.

AstraZeneca’s COPD treatment Bevespi Aerosphere fails in phase IIIb trial

AstraZeneca’ Bevespi Aerosphere (glycopyrronium/formoterol fumarate) has failed to demonstrate superiority against umeclidinium/vilanterol in treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in the phase IIIb trial.

Pfizer, Astellas amend clinical research protocols for two phase 3 trials of Enzalutamide

Pfizer and Astellas Pharma have announced amendments to the protocols for two registrational phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of XTANDI (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).

Can-Fite enrolls first patient in phase 3 trial of Piclidenoson in psoriasis

Can-Fite BioPharma has enrolled and dosed the first patient in its phase 3 Comfort trial to evaluate its small orally bioavailable drug Piclidenoson (CF101) for the treatment of moderate-to-severe plaque psoriasis.

Rexahn partners with Merck on combo study in TNBC

Merck has signed a clinical trial collaboration agreement with Rexahn Pharmaceuticals to assess the combination of RX-5902 (Supinoxin) and Keytruda (pembrolizumab) in a breast cancer trial.